NEW YORK(GenomeWeb) – Natera plans to offer 6.25 million shares of its stock in its initial public offering, raising up to $103.3 million in net proceeds, it said in a document filed with the US Securities and Exchange Commission today. 

In an amended Form S-1, the San Carlos, California-based non-invasive prenatal testing firm said it plans to price its shares at between $15 and $17. At the midpoint price of $16, net proceeds from the offering are anticipated to be $89.3 million, or $103.3 million if the underwriters exercise their overallotment option in full. 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Genetic ancestry testing can affect a person's sense of identity, the New York Times Magazine writes.

Nebula Genomics is launching its genome sequencing service for free for people who provide certain information about themselves, the Boston Globe reports.

In PLOS this week: grey wolf population genomics, mutations associated with lung adenocarcinoma survival, and more.

An opinion piece at Bloomberg discusses China's stance on genomic research.

Sponsored by

This webinar will discuss how understanding the relative performance characteristics of glass and polymer substrates for in vitro diagnostic applications such as microarrays and microfluidics can help to optimize diagnostic performance.

Sponsored by
Advanced Cell Diagnostics

This webinar will demonstrate how a research team at the National Institutes of Health evaluated a novel in situ hybridization approach and applied it to study splice variants related to schizophrenia.

Sponsored by
Sophia Genetics

This webinar will discuss the use of clinical-grade exome analysis application in complex case investigations.

Sponsored by

This webinar will discuss the use of shotgun metagenomics to identify children at risk of hospital-acquired infection.